Li Ming-Yi, Deng Hua, Zhao Jia-Ming, Dai Dong, Tan Xiao-Yu
Department of General Surgery, Affiliated Hospital of Guangdong Medical College, Zhangjiang 524001, Guangdong Province, China.
World J Gastroenterol. 2003 Aug;9(8):1683-8. doi: 10.3748/wjg.v9.i8.1683.
To investigate the characteristics of PPAR gamma ligands induced apoptosis in liver cancer cells.
The effects of ligands for each of the PPAR gamma ligands on DNA synthesis and cell viability were examined in BEL-7402 liver cancer cells. Apoptosis was characterized by Hochest33258 staining, DNA fragmentation, TUNEL and ELISA, and cell cycle kinetics by FACS. Modulation of apoptosis related caspases expression by PPAR gamma ligands was examined by Western blot.
PPARgamma ligands, 15-deoxy-(12), (14)-prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), suppressed DNA synthesis of BEL-7402 cells. Both 15d-PGJ2 and TGZ induced BEL-7402 cell death in a dose dependent manner, which was associated with an increase in fragmented DNA and TUNEL-positive cells. At concentrations of 10 and 30 microM, 15d-PGJ(2) or troglitazone increased the proportion of cells with G(0)/G(1) phase DNA content and decreased those with S phase DNA content. There was no significant change in the proportion of cells with G(2)/M DNA content. The activities of Caspases-3, -6, -7 and -9 were increased by 15d-PGJ2 and TGZ treatment, while the activity of Caspase 8 had not significantly changed.
The present results suggest the potential usefulness of PPAR gamma ligands for chemoprevention and treatment of liver cancers.
研究过氧化物酶体增殖物激活受体γ(PPARγ)配体诱导肝癌细胞凋亡的特性。
检测了各PPARγ配体对BEL - 7402肝癌细胞DNA合成及细胞活力的影响。采用Hochest33258染色、DNA片段化分析、TUNEL法及酶联免疫吸附测定(ELISA)对细胞凋亡进行鉴定,通过流式细胞术(FACS)分析细胞周期动力学。采用蛋白质免疫印迹法检测PPARγ配体对凋亡相关半胱天冬酶表达的调节作用。
PPARγ配体15 - 脱氧 - (12),(14)-前列腺素J2(15d - PGJ2)和曲格列酮(TGZ)抑制了BEL - 7402细胞的DNA合成。15d - PGJ2和TGZ均以剂量依赖性方式诱导BEL - 7402细胞死亡,这与DNA片段化增加及TUNEL阳性细胞增多有关。在10和30微摩尔浓度下,15d - PGJ2或曲格列酮增加了G0/G1期DNA含量细胞的比例,降低了S期DNA含量细胞的比例。G2/M期DNA含量细胞的比例无显著变化。15d - PGJ2和TGZ处理可增加半胱天冬酶 - 3、 - 6、 - 7和 - 9的活性,而半胱天冬酶8的活性无显著变化。
目前的结果表明PPARγ配体在肝癌化学预防和治疗方面具有潜在的应用价值。